Glaukos Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas William Burns
- Full Time Employees
- 1,094
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- One Glaukos Way Aliso Viejo CA United States of America 92656
- IPO Date
- Jun 25, 2015
- CIK
- 0001192448
- Website
- glaukos.com
- Similar Companies
- Business
- Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Founded in 1998 and headquartered in Aliso Viejo, California, Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) technology, launching the first MIGS device commercially in 2012. Its core products include the iStent family of micro-scale surgical devices to reduce intraocular pressure in glaucoma patients; the iDose TR, a first-of-its-kind, long-duration intracameral procedural pharmaceutical implant delivering continuous glaucoma drug therapy inside the eye; a proprietary, FDA-approved corneal cross-linking therapy for keratoconus; transdermal pharmaceuticals for treating glaucoma, dry eye, presbyopia, and ocular surface diseases; and bio-erodible sustained-release drug delivery implants for retinal diseases. The company operates globally with locations in the United States, Canada, the United Kingdom, Germany, Japan, Australia, and Brazil. Recent major developments include the commercial launch of the iDose TR implant in 2024, which delivers sustained glaucoma drug therapy, marking a significant advancement in dropless therapies. In 2025, Glaukos reported record net sales with notable growth in glaucoma product sales, raised full-year 2025 revenue guidance to $490 million to $495 million, and issued preliminary 2026 sales guidance of $600 million to $620 million. The company also received FDA approval for a new eye therapy named Epioxa, expected to be commercially available in early 2026. Glaukos continues to invest in expanding its pipeline of novel dropless platform technologies aimed at improving patient outcomes and advancing the standard of care across its ophthalmic focus areas. It maintains a strong financial position with no debt and substantial cash reserves as of the third quarter of 2025. Glaukos' shares trade on the New York Stock Exchange under the ticker symbol GKOS.
Company News
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
Glaukos Corporation $GKOS Shares Sold by Squarepoint Ops LLC
Corient Private Wealth LP Takes Position in Glaukos Corporation $GKOS
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos Corporation $GKOS Stock Holdings Trimmed by Algert Global LLC
61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos Announces Participation in Wells Fargo Healthcare Conference
Which Small-Cap ETF Is the Better Buy: iShares' Growth-Focused IWO or Invesco's Revenue-Weighted RWJ?
First Trust Advisors LP Acquires 40,798 Shares of Glaukos Corporation $GKOS
Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
Glaukos Q2 Earnings Call Highlights
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos Announces Second Quarter 2026 Financial Results
Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 Release
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt